Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda

Reuters

Sep 04

Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda

GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564371273"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564371273\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564371273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564371273","market":"fut","top_or_hot":-1,"title":"Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7KhvNT:1","article_id":"2564371273","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564371273","pubTimestamp":1756987380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc.  has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4547":"WSB热门概念","BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax的Nuvaxovid®COVID-19疫苗在日本获得监管批准，触发武田的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    \n\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}